|Bid||37.98 x 900|
|Ask||38.02 x 1200|
|Day's range||37.75 - 38.15|
|52-week range||31.43 - 48.25|
|Beta (5Y monthly)||0.32|
|PE ratio (TTM)||38.33|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||2.05 (5.32%)|
|Ex-dividend date||12 Nov 2020|
|1y target est||48.50|
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
Shares of Vir Biotechnology (NASDAQ: VIR) were vaulting 12.8% higher as of 3:07 p.m. EST on Tuesday. The big jump came after the company announced news about separate collaborations with Gilead Sciences (NASDAQ: GILD) and GlaxoSmithKline (NYSE: GSK). Vir and Gilead plan to work together on a phase 2 study evaluating Vir's VIR-2218 with Gilead's selgantolimod in treating individuals infected with the hepatitis B virus (HBV).
The Zacks Analyst Blog Highlights: UnitedHealth Group, Netflix, Caterpillar, General Electric and GlaxoSmithKline